ArticleOpen Access http://dx.doi.org/10.26855/ijcemr.2025.11.009
The Impact of Labetalol Combined with Low-molecular-weight Heparin on Arterial Blood Flow Indicators and Maternal-fetal Outcomes in Pregnancy-induced Hypertension
Mei Cao*, Jingjing Zhang, Yuanjun Zhu, Hao Yin, Heng Yin, Xueqin Liu
Department of Obstetrics and Gynecology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
*Corresponding author: Mei Cao
Published: November 28,2025
Abstract
Objective: To investigate the impact of labetalol combined with low-molecular-weight heparin on arterial blood flow indices and maternal-fetal outcomes in gestational hypertension. Methods: A total of 62 patients diagnosed with gestational hypertension between January 2023 and June 2024 were included as study subjects. Patients were randomly assigned to either the control group (treated with labetalol) or the observation group (treated with labetalol combined with low-molecular-weight heparin). Blood pressure levels, arterial blood flow indices (end-diastolic velocity peak [EDV], systolic velocity peak [PSV]), and maternal-fetal outcomes were compared between the two groups. Results: After treatment, the diastolic and systolic blood pressure levels in the observation group were lower than those in the control group (P < 0.05). Post-treatment, the EDV and PSV values in the observation group were higher than those in the control group (P < 0.05). The total incidence of adverse maternal-fetal outcomes was lower in the observation group compared to the control group (P < 0.05). Conclusion: The use of labetalol combined with low-molecular-weight heparin in treating gestational hypertension can reduce blood pressure levels, improve arterial blood flow indices, and enhance maternal-fetal outcomes.
Keywords
Labetalol; Low-molecular-weight heparin; Hypertension during pregnancy; Arterial blood flow; Maternal and fetal outcomes
References
[1] Ayodeji A. Sanusi, Justin Leach, et al. Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension. Obstet Gynecol. 2024;144(1):126-34.
[2] Bai SM. The effect of low molecular weight heparin combined with nifedipine controlled-release tablets on blood pressure and maternal and infant outcomes in patients with hypertension during pregnancy. Shanxi Med J. 2024;53(13):1018-21.
[3] Bone JN, Sandhu A, et al. Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. Hypertension. 2022;79(3):614-28.
[4] Hou Q, Zhang XJ. The effect of low molecular weight heparin sodium combined with magnesium sulfate and labetalol on blood pressure levels, coagulation function and pregnancy outcomes in patients with severe gestational hypertension. Reflexol Rehabil Med. 2024;5(16):113-5,119.
[5] Huang Y, Zhao Y. The effect of aspirin combined with low molecular weight heparin in the adjuvant treatment of hypertension during pregnancy and its impact on delivery outcomes. Clin Ration Drug Use. 2024;17(20):124-6.
[6] Li S, Song H, Bie YH. The effect of low molecular weight heparin in the treatment of moderate to severe hypertensive disorders of pregnancy. Int J Transplant Blood Purif. 2024;22(5):5-7.
[7] Li YM, Li LN, Chen YJ. The effect of low molecular weight calcium heparin on blood pressure levels and coagulation function indicators in patients with hypertension during pregnancy. In: Proceedings of the 2024 Second Clinical Medicine Academic Symposium of "Chinese Journal of Histochemistry and Cytochemistry" (Part I); 2024. p. 1-6.
[8] Muhammad S, Usman, et al. Comparison of intravenous labetalol and hydralazine for severe hypertension in pregnancy in North-eastern Nigeria: A randomized controlled trial. Pregnancy Hypertens. 2022;29:1-6.
[9] The Obstetrics and Gynecology Group on Hypertensive Disorders of Pregnancy, Chinese Medical Association. Guidelines for the Diagnosis and Treatment of Hypertensive Disorders of Pregnancy (2020). Chin J Obstet Gynecol. 2020;55(4):227-38.
[10] Zhang YP, Wang ZM, Yu Z. The effect of low molecular weight heparin sodium combined with nifedipine in the treatment of hypertension during pregnancy and its impact on pregnancy outcomes. Chin J Pract Med. 2024;51(14):109-12.
How to cite this paper
The Impact of Labetalol Combined with Low-molecular-weight Heparin on Arterial Blood Flow Indicators and Maternal-fetal Outcomes in Pregnancy-induced Hypertension
How to cite this paper: Mei Cao, Jingjing Zhang, Yuanjun Zhu, Hao Yin, Heng Yin, Xueqin Liu. (2025) The Impact of Labetalol Combined with Low-molecular-weight Heparin on Arterial Blood Flow Indicators and Maternal-fetal Outcomes in Pregnancy-induced Hypertension. International Journal of Clinical and Experimental Medicine Research, 9(6), 631-635.
DOI: http://dx.doi.org/10.26855/ijcemr.2025.11.009